Trends and variability in the use of glucocorticoids in patients with systemic lupus erythematosus included in the RELESSER-PROS registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rua-Figueroa Inigo, Fernández-Fernández David, Plaza Zulema, Roberts Karen, Serrano-Benavente Belén, Galindo-Izquierdo María, Calvo Alen Jaime, Menor Raúl, Mena-Vázquez Natalia, Uriarte Esther, Tomero Eva, Freire Mercedes, Sanguesa Clara, Gómez-Sabater Silvia, Horcada Loreto, Lozano-Rivas Nuria, García-Villanueva María Jesús, Quevedo-Rodríguez Adrián, Díez-Álvarez Elvira, Narváez Javier, Iñiguez Carlota, Loricera Javier, Novoa Javier, Ruiz-Lucea Esther, Rosas José, Expósito Lorena, Carrión-Barbera Irene, Salgado Eva, Andreu José Luis, Aurrecoechea Elena, Montilla Carlos, Román Ivorra Jose Andrés, Bonilla Gema, Cobo-Ibañez Tatiana, Muñoz-Jiménez Alejandro, Torrente-Segarra Vicente, Arévalo-Salaet Marta, Pecondón-Español Angela, Pérez-Gómez Ana, Flores Eduardo, Pego-Reigosa Jose M
Аннотация
METHODS: Observational, descriptive, longitudinal, and prospective study of patients with SLE included in RELESSER-PROS regarding patterns of GC use.
RESULTS: 1432 patients were included, 89.8% women, mean age 56 years (±13.6), median follow-up 3.80 [2.06, 4.18] years, from 2015 to 2021. Median S-SLEDAI (5 visits): 2.00 [Q-Q3] [0-4.00], PGA: 0.3 [0, 0.9]. Median SLICC/ARC DI: 0 [0-1.00], mean: 0.83 (±1.20). Between 30% and 61% of patients received GC at baseline and between 17% and 50% at the end (V5). A progressive decrease in the percentage of patients receiving GC was observed in most AC, reaching the minimum at V5. Between 71.45% and 89.47% of patients, by autonomous community, met the criterion of ≤5 mg of prednisone at V5, with a delta between the autonomous community with the highest percentage and the lowest of 18 points. This percentage increased between visit 1 and visit 5 in all cases.
CONCLUSIONS: The use of low-dose GCs is common in Spanish lupus patients, although there is a clear downward trend in their use. Most patients typically reach the recommended dose. There are differences between the different autonomous communities in the use of GCs and their dosage.